Oct 27, 2026 · 38 min · 9 segments
As always, we have the most interesting (and important) news from the pharmacy compounding world, plus this episode we’ve got a deep dive into a future for peptides that protects patients while giving…
Philip SmithGuestScott BrunerGuestAndrew KantorHostFederal prosecutors charged two Indian nationals with conspiracy and smuggling for, allegedly, trying to bring into the country counterfeit Ozempic they obtained from unauthorized Chinese sources.
We're not talking just the drug, but packaging, inserts, labeling, needles, the whole shebang.
It's clearly a very different animal than licensed pharmacy compounding, no matter how much drug makers try to muddy those waters.
And it also makes pretty clear that regulators have and use their ability to fight counterfeiters.
Some of the big issues in the compounding world that we've covered here are pretty complex.
And APC has just published a couple of pages on our website to help make sense out of them and how we think regulators ought to handle them.
We'll talk in detail about peptide policy in a minute with our deep dive, but we have created a one-stop shop for all the background on the issue, along with our recommendations for how it should be handled and how it can help keep patients safe and away from these shady pop-up peptide shops.
You'll find this at a4pc.org slash peptides, and there's a link in the show notes.
The other page we've launched covers animal-derived thyroid products, ADT or DTE for desiccated thyroid extract.
We've compiled a bunch of information on the subject, including what your patients can do to protect their access.
If you dispense compounded meds to California, but you don't live there, you might be aware that the State Board of Pharmacy is proposing raising the annual fees for out-of-state compounding pharmacies and outsourcing facilities.
to $15,000 a year, while out-of-state outsourcing facilities would see an increase of 32% to $37,500 a year.
Federal prosecutors charged two Indian nationals with conspiracy and smuggling for, allegedly, trying to bring into the country counterfeit Ozempic they obtained from unauthorized Chinese sources.
We're not talking just the drug, but packaging, inserts, labeling, needles, the whole shebang.
It's clearly a very different animal than licensed pharmacy compounding, no matter how much drug makers try to muddy those waters.
And it also makes pretty clear that regulators have and use their ability to fight counterfeiters.
Some of the big issues in the compounding world that we've covered here are pretty complex.
And APC has just published a couple of pages on our website to help make sense out of them and how we think regulators ought to handle them.
We'll talk in detail about peptide policy in a minute with our deep dive, but we have created a one-stop shop for all the background on the issue, along with our recommendations for how it should be handled and how it can help keep patients safe and away from these shady pop-up peptide shops.
You'll find this at a4pc.org slash peptides, and there's a link in the show notes.
The other page we've launched covers animal-derived thyroid products, ADT or DTE for desiccated thyroid extract.
We've compiled a bunch of information on the subject, including what your patients can do to protect their access.
If you dispense compounded meds to California, but you don't live there, you might be aware that the State Board of Pharmacy is proposing raising the annual fees for out-of-state compounding pharmacies and outsourcing facilities.
to $15,000 a year, while out-of-state outsourcing facilities would see an increase of 32% to $37,500 a year.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
